ReviewDiagnostics (Basel, Switzerland)2024
An Assessment of the Feasibility, Patient Acceptance, and Performance of Point-of-Care Transient Elastography for Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-Analysis.
Review in Diagnostics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Diagnostic performance of ultrasound-derived fat fraction for grading hepatic steatosis in patients with chronic liver diseases: a multicenter study.European radiology · 2026Article
- The Use of Ultrasound-Based Elastography Techniques in Liver Fibrosis: A Narrative Review.Diagnostics (Basel, Switzerland) · 2026Review
- Diagnostic innovation and models of care to improve fibrosis detection and risk stratification in steatotic liver disease.The Lancet regional health. Europe · 2026Review
- Diagnostic Value of Neutrophil-to-Lymphocyte Ratio and Mean Platelet Volume as Predictors of Liver Fibrosis Severity in MASLD: A Cross-Sectional Study.Health science reports · 2026Article
- Associations of relative fat mass with metabolic dysfunction-associated steatotic liver disease and liver fibrosis: evidence from the U.S. NHANES 2017-2023.BMC gastroenterology · 2026Article
- Article
- Imaging-based fibrosis assessment and risk stratification in MASLD.Frontiers in medicine · 2026Review
- Divergent Trajectories of the Burden of MASLD Attributable to High Fasting Plasma Glucose in China and Globally: A GBD Study 1990-2021 and Projections to 2046.Gastroenterology research and practice · 2026Article
- Comparison between vibration-controlled transient elastography and point shear wave elastography for assessment of hepatic fibrosis based on magnetic resonance elastography.Ultrasonography (Seoul, Korea) · 2025Article
- Impact of Short-Term Liraglutide Therapy on Non-Invasive Markers of Liver Fibrosis in Patients with MASLD.Metabolites · 2025Article
- Article
- Alcohol Consumption and Liver Metabolism in the Era of MASLD: Integrating Nutritional and Pathophysiological Insights.Nutrients · 2025Review
- Visceral adiposity index as a predictor of metabolic dysfunction-associated steatotic liver disease: a cross-sectional study.BMC gastroenterology · 2025Article
- Non-Invasive Tests as a Replacement for Liver Biopsy in the Assessment of MASLD.Medicina (Kaunas, Lithuania) · 2025Review
- The Effects of Oral Semaglutide on Hepatic Fibrosis in Subjects with Type 2 Diabetes in Real-World Clinical Practice: A Post Hoc Analysis of the Sapporo-Oral SEMA Study.Pharmaceuticals (Basel, Switzerland) · 2025Article
- EUS point shear-wave elastography: A novel approach for noninvasive liver fibrosis assessment.Endoscopic ultrasoundArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.